InterVenn Biosciences to Participate at Two Upcoming Investor Conferences in November

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--InterVenn Biosciences today announced that company management will participate at the following virtual investor conferences:

Stifel 2021 Virtual Healthcare Conference
Formal presentation on Tuesday, November 16, 2021 at 11:00 a.m. PT / 2:00 p.m. ET
Canaccord Genuity Virtual MedTech, Diagnostics, and Digital Health & Services Forum
Fireside chat on Thursday, November 18, 2021 at 1:00 p.m. PT / 4:00 p.m. ET

A live webcast of the Stifel event will be available on the “For Investors” section of the InterVenn website at https://intervenn.com/investors/ and will be available for 90 days thereafter.

About InterVenn Biosciences

InterVenn Biosciences utilizes a proprietary glycoproteomic biomarker interrogation platform using AI and mass spectrometry for next-gen precision medicine. The company is working to find new solutions in ovarian, pancreatic, liver, prostate, and kidney cancer, together with applications from the PerspectIV™ suite of solutions for treatment and monitoring, immune profiling, patient stratification, and disease progression. For more information about InterVenn Biosciences, please visit the company’s website.

Contacts

Andrea Vuturo
press@venn.bio
(888) 706-1670

Industry:

InterVenn Biosciences

Details

Headquarters: South San Francisco, California

Website: https://intervenn.com/

CEO: Andrew Quong, Ph.D.

Employees: 51-200

Organization: PRI

Release Summary

InterVenn Biosciences announces their participation in investor conferences: Stifel 2021 Healthcare Conference and Canaccord Genuity Virtual Forum.

Release Versions

English

Contacts

Andrea Vuturo
press@venn.bio
(888) 706-1670

Social Media Profiles

InterVenn on Facebook

InterVenn on LinkedIn

More News From InterVenn Biosciences

InterVenn Receives AMA PLA Code for Non-Invasive Ovarian Cancer Diagnostic

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--InterVenn receives AMA PLA code for GlycoKnow™ Ovarian, its first non-invasive diagnostic for distinguishing malignant from benign pelvic masses....

InterVenn Presents Results Detailing Glycoproteomic Signature Predictive of Response to Immune Checkpoint Inhibitor Treatment in Advanced Non-Small Cell Lung Cancer at American Society for Immunotherapy of Cancer

WASHINGTON--(BUSINESS WIRE)--InterVenn presents results at SITC on a predictive signature capable of identifying NSCLC patients that will benefit most from checkpoint inhibitors...